Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, has announced its plans to report second quarter 2024 financial results on Monday, August 12, 2024, after market close. The company will host a conference call at 4:30 p.m. Eastern time to discuss the results and provide a business update.
Participants must pre-register for the conference call through a provided link. Registered participants will receive email instructions with dial-in options. To ensure a smooth experience, participants are encouraged to dial in 15 minutes before the scheduled start time. Additionally, a live webcast of the call will be available on Lisata's website under the Investors & News section, with a replay accessible for 12 months following the call.
Lisata Therapeutics (Nasdaq: LSTA), un'azienda farmaceutica in fase clinica focalizzata sullo sviluppo di terapie innovative per tumori solidi avanzati e altre malattie gravi, ha annunciato i suoi piani per comunicare i risultati finanziari del secondo trimestre 2024 il lunedì 12 agosto 2024, dopo la chiusura del mercato. L'azienda organizzerà una conference call alle 16:30 ora orientale per discutere i risultati e fornire aggiornamenti aziendali.
I partecipanti devono preregistrarsi per la conference call tramite un link fornito. I partecipanti registrati riceveranno istruzioni via email con le opzioni di accesso telefonico. Per garantire un'esperienza fluida, si consiglia ai partecipanti di collegarsi 15 minuti prima dell'orario di inizio programmato. Inoltre, una trasmissione in diretta della chiamata sarà disponibile sul sito web di Lisata nella sezione Investitori e Notizie, con una registrazione accessibile per 12 mesi dopo la chiamata.
Lisata Therapeutics (Nasdaq: LSTA), una empresa farmacéutica en etapa clínica centrada en desarrollar terapias innovadoras para tumores sólidos avanzados y otras enfermedades graves, ha anunciado sus planes de informar sobre los resultados financieros del segundo trimestre de 2024 el lunes 12 de agosto de 2024, después del cierre del mercado. La empresa celebrará una conferencia telefónica a las 4:30 p.m. hora del este para discutir los resultados y proporcionar una actualización empresarial.
Los participantes deben preinscribirse para la conferencia telefónica a través de un enlace proporcionado. Los participantes registrados recibirán instrucciones por correo electrónico con opciones de acceso por teléfono. Para asegurar una experiencia fluida, se alienta a los participantes a llamar 15 minutos antes de la hora programada. Además, se dispondrá de una transmisión en vivo de la llamada en el sitio web de Lisata en la sección de Inversores y Noticias, con una repetición accesible durante 12 meses después de la llamada.
리사타 테라퓨틱스(Lisata Therapeutics, Nasdaq: LSTA)는 고형암 및 기타 심각한 질병을 위한 혁신적인 치료제를 개발하는 임상 단계 제약 회사로, 2024년 2분기 재무 결과를 2024년 8월 12일 월요일 시장 종료 후 발표할 계획이라고 발표했습니다. 회사는 동부 표준시 기준 오후 4시 30분에 결과를 논의하고 비즈니스 업데이트를 제공하기 위해 콘퍼런스 콜을 개최할 것입니다.
참가자는 제공된 링크를 통해 콘퍼런스 콜에 사전 등록해야 합니다. 등록된 참가자는 전화 접속 옵션과 함께 이메일 지침을 받을 것입니다. 원활한 경험을 보장하기 위해 참가자는 예정된 시작 시간 15분 전에 전화 접속을 권장합니다. 또한, 리사타의 웹사이트 투자자 및 뉴스 섹션을 통해 콜의 실시간 웹캐스트가 제공되며, 통화 후 12개월 동안 다시 시청할 수 있습니다.
Lisata Therapeutics (Nasdaq: LSTA), une entreprise pharmaceutique en phase clinique spécialisée dans le développement de thérapies innovantes pour les tumeurs solides avancées et d'autres maladies graves, a annoncé ses projets de publier les résultats financiers du deuxième trimestre 2024 le lundi 12 août 2024, après la clôture du marché. L'entreprise organisera une conférence téléphonique à 16h30 heure de l'Est pour discuter des résultats et fournir une mise à jour de l'entreprise.
Les participants doivent se pré-inscrire pour la conférence téléphonique via un lien fourni. Les participants enregistrés recevront des instructions par e-mail avec des options de connexion. Pour garantir une expérience fluide, il est conseillé aux participants de se connecter 15 minutes avant l'heure de début prévue. De plus, une retransmission en direct de l'appel sera disponible sur le site web de Lisata dans la section Investisseurs & Actualités, avec un replay accessible pendant 12 mois après l'appel.
Lisata Therapeutics (Nasdaq: LSTA), ein in der klinischen Phase befindliches Pharmaunternehmen, das sich auf die Entwicklung innovativer Therapien für fortgeschrittene solide Tumoren und andere schwerwiegende Krankheiten konzentriert, hat seine Pläne bekannt gegeben, die Finanzergebnisse für das zweite Quartal 2024 am Montag, den 12. August 2024, nach Börsenschluss zu veröffentlichen. Das Unternehmen wird eine Telefonkonferenz um 16:30 Uhr Eastern Time abhalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben.
Die Teilnehmer müssen sich über einen bereitgestellten Link für die Telefonkonferenz vorregistrieren. Registrierte Teilnehmer erhalten per E-Mail Anleitungen mit Dial-in-Optionen. Um ein reibungsloses Erlebnis zu gewährleisten, werden die Teilnehmer ermutigt, 15 Minuten vor der geplanten Startzeit anzurufen. Zudem wird eine Live-Übertragung der Konferenz auf der Website von Lisata im Bereich Investoren & Nachrichten verfügbar sein, mit einer Wiederholung, die 12 Monate nach der Konferenz zugänglich ist.
- None.
- None.
BASKING RIDGE, N.J., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results the second quarter ended June 30, 2024, on Monday, August 12, 2024, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.
Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details with dial-in options. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time.
A live webcast of the call will also be accessible under the Investors & News section of Lisata’s website and will be available for replay beginning two hours after the conclusion of the call for 12 months.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s product candidate, certepetide (formerly LSTA1), is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next two years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. For more information on the Company, please visit www.lisata.com.
Contact:
Investors
Lisata Therapeutics, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
Media:
ICR Westwicke
Elizabeth Coleman
Senior Associate
Phone: 203-682-4783
Email: elizabeth.coleman@westwicke.com
FAQ
When will Lisata Therapeutics (LSTA) report its Q2 2024 financial results?
What time is Lisata Therapeutics' (LSTA) Q2 2024 earnings call scheduled for?
How can investors participate in Lisata Therapeutics' (LSTA) Q2 2024 earnings call?
What is Lisata Therapeutics' (LSTA) primary focus as a company?
